CA2508264A1 - Methods of treatment of ulcerative colitis with anti-cd3 antibodies - Google Patents

Methods of treatment of ulcerative colitis with anti-cd3 antibodies Download PDF

Info

Publication number
CA2508264A1
CA2508264A1 CA002508264A CA2508264A CA2508264A1 CA 2508264 A1 CA2508264 A1 CA 2508264A1 CA 002508264 A CA002508264 A CA 002508264A CA 2508264 A CA2508264 A CA 2508264A CA 2508264 A1 CA2508264 A1 CA 2508264A1
Authority
CA
Canada
Prior art keywords
antibody
patients
visilizumab
patient
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002508264A
Other languages
English (en)
French (fr)
Inventor
Ian Walters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2508264A1 publication Critical patent/CA2508264A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CA002508264A 2002-12-05 2003-12-05 Methods of treatment of ulcerative colitis with anti-cd3 antibodies Abandoned CA2508264A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43164902P 2002-12-05 2002-12-05
US60/431,649 2002-12-05
US45018303P 2003-02-25 2003-02-25
US60/450,183 2003-02-25
PCT/US2003/038809 WO2004052397A1 (en) 2002-12-05 2003-12-05 Methods of treatment of ulcerative colitis with anti-cd3 antibodies

Publications (1)

Publication Number Publication Date
CA2508264A1 true CA2508264A1 (en) 2004-06-24

Family

ID=32511592

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002508264A Abandoned CA2508264A1 (en) 2002-12-05 2003-12-05 Methods of treatment of ulcerative colitis with anti-cd3 antibodies

Country Status (7)

Country Link
US (1) US20040253237A1 (https=)
EP (1) EP1567192A4 (https=)
JP (1) JP2006511620A (https=)
KR (1) KR20050091713A (https=)
AU (1) AU2003298015A1 (https=)
CA (1) CA2508264A1 (https=)
WO (1) WO2004052397A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1687066T3 (da) 2003-11-14 2012-11-26 Brigham & Womens Hospital Fremgangsmåder til immunmodulering
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
WO2007026742A1 (ja) * 2005-08-30 2007-03-08 Ajinomoto Co., Inc. 大腸デリバリー型炎症性大腸疾患治療薬
AR057807A1 (es) * 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
AU2012201443B2 (en) * 2006-06-06 2014-04-03 Glaxo Group Limited Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
JP2009539841A (ja) * 2006-06-06 2009-11-19 トラークス，インコーポレイテッド 自己免疫疾患の治療における抗ｃｄ３抗体の投与
RS67768B1 (sr) 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
US11001631B2 (en) 2016-02-05 2021-05-11 Orionis Biosciences BV Clec9A binding agents
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
US20210138213A1 (en) * 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN118562007A (zh) * 2019-12-19 2024-08-30 苏州方德门达新药开发有限公司 工程改造的t细胞、其制备及应用
CN119095873A (zh) 2022-03-14 2024-12-06 拉姆卡普生物伽马股份公司 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DE19905012A1 (de) * 1999-02-08 2000-08-10 Gsf Forschungszentrum Umwelt Arzneimittel enthaltend Anti-CD3- und Anti-Fcgamma-R-Antikörper zur begleitenden Behandlung bei Organtransplantationen
US20040219142A1 (en) * 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors

Also Published As

Publication number Publication date
KR20050091713A (ko) 2005-09-15
US20040253237A1 (en) 2004-12-16
WO2004052397A1 (en) 2004-06-24
AU2003298015A1 (en) 2004-06-30
JP2006511620A (ja) 2006-04-06
EP1567192A4 (en) 2006-02-08
EP1567192A1 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
US20040253237A1 (en) Methods of treatment of ulcerative colitis with anti-CD3 antibodies
US20220288199A1 (en) Therapeutic RNA and Anti-PD1 Antibodies for Advanced Stage Solid Tumor Cancers
US20250051446A1 (en) Anti-CD28 Humanized Antibodies Formulated for Administration to Humans
US11591395B2 (en) Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
JP2024120911A (ja) 好中球性病態の治療方法
TW202302143A (zh) 重症肌無力症之治療或預防用之醫藥組合物
US20250064956A1 (en) Methods for treating muscle invasive urothelial cancer or muscle invasive bladder cancer with antibody drug conjugates (adc) that bind to 191p4d12 proteins
US20070224191A1 (en) Methods of treatment of Ulcerative Colitis and Crohn's disease with anti-CD3 antibodies
US20250376516A1 (en) Method of administration of an anti-ifn-alpha/-omega antibody
US20250059290A1 (en) Anti-ox40 antagonistic antibodies for the treatment of autoimmune diseases
US20080050364A1 (en) Treatment of LFA-1 Associated Disorders with Increasing Doses of LFA-1 Antagonist
CA3228514A1 (en) Method and composition for inducing tolerance
CA2486147A1 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
US20240190970A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
TW202417052A (zh) 以結合191p4d12蛋白質之抗體藥物結合物(adc)組合派姆單抗(pembrolizumab)治療局部晚期或轉移性尿路上皮癌之患者之方法
US6652855B1 (en) Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
US20260042831A1 (en) Methods of treating sarcoidosis with a tnf-a antibody and associated compositions and methods
WO2025198912A1 (en) Methods of treating myasthenia gravis
TW202515622A (zh) 用結合１９１ｐ４ｄ１２蛋白之抗體藥物結合物（ａｄｃ）與派姆單抗之組合治療局部晚期或轉移性尿路上皮癌患者之方法
HK40110527A (zh) 伊奈利珠单抗及其在治疗或预防igg4相关疾病中的使用方法
CN116490520A (zh) 用于covid-19肺炎的托珠单抗和瑞德西韦组合疗法
HK1245666B (en) Compositions comprising a dual v region antibody-like protein
HK1245666A1 (en) Compositions comprising a dual v region antibody-like protein
HK1110024A (en) Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist

Legal Events

Date Code Title Description
FZDE Discontinued